BIO

Bio Rad Laboratories Inc

Life Sciences Tools & Services

+ WatchlistView SEC Filings

Bio Rad Laboratories Inc (BIO) Stock News

The latest BIO headlines and market coverage — 10 recent stories, updated throughout the day.

• GlobeNewswire Inc.·1d ago

  SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

  SL BIO Ltd. completed its business combination with Horizon Space Acquisition II Corp., creating SL Science Holding Limited, which began trading on Nasdaq under ticker 'SLBT' on June 15, 2026. The transaction valued SL Bio at approximately $5.568 billion and raised $7.8 million in PIPE financing. The company plans to advance its proprietary Gamma delta T cell-based cellular therapies for solid tumors, including pancreatic and brain cancers, leveraging Nasdaq listing to access U.S. capital markets and pursue strategic growth.

• GlobeNewswire Inc.·3d ago

  BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-Q Filing

  BIO-key International (BKYI) received a notification letter from Nasdaq on June 10, 2026, stating the company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, in violation of Nasdaq Listing Rule 5250(c)(1). The Nasdaq Hearing Panel will determine whether the company can maintain its listing on the Nasdaq Capital Market.

• The Motley Fool·12d ago

  Bioceres (BIOX) Q3 2026 Earnings Transcript

  Bioceres reported Q3 2026 results showing significant operational challenges, including a $10 million net loss, 23% revenue decline to $39.4 million, and a $179 million noncash loss from the Pro Farm foreclosure. The company faces substantial litigation from noteholders, short-term debt acceleration, and liquidity pressure with only $14 million in cash against $229 million in debt. Management is pursuing cost reductions and working capital discipline while defending against legal challenges.

• GlobeNewswire Inc.·15d ago

  GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

  A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo response controls at Latin American testing sites, causing investors to purchase securities at artificially inflated prices. Investors who purchased shares between June 16, 2025, and February 20, 2026, have until June 1, 2026, to apply as lead plaintiff.

• Benzinga·15d ago

  COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

  REHOVOT, Israel , May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN ), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the first quarter of 2026, we initiated discussions with several leading strategic players to explore potential collaborations, primarily in the medical aesthetics field," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant Biotechnologies. "These discussions are focused on the potential joint development and commercialization of next-generation dermal filler product candidates incorporating CollPlant's rhCollagen technology in combination with hyaluronic acid and additional components. We are actively advancing these discussions and, while no assurance can be provided, remain encouraged by the level of interest and the progress achieved to date." Mr. Tal continued: "CollPlant is also advancing development of its next-generation photocurable dermal filler platform based on rhCollagen technology, designed to provide immediate structural support together with the potential for long-term tissue regeneration. The product candidate, currently in the final preclinical stage, is intended to address age-related volume loss and facial changes associated with significant weight reduction. During the quarter, the Korean Patent Office granted CollPlant a patent covering key aspects of the photocurable dermal filler technology, further strengthening our intellectual property portfolio in regenerative aesthetics." "The Company is planning to establish a broader portfolio of regenerative dermal and soft tissue fillers and is targeting initiation of clinic

• GlobeNewswire Inc.·18d ago

  NANOBIOTIX Announces Closing of Global Offering

  Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.

• GlobeNewswire Inc.·18d ago

  NANOBIOTIX annonce le règlement-livraison de son offre globale

  NANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%), Nanoprimer and other platforms (50-60%), and general corporate needs (30-40%), with sufficient runway through 2029.

• GlobeNewswire Inc.·26d ago

  IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

  A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that defendants made false and misleading statements regarding Anktiva's capabilities and the company's business operations during the Class Period (January 19, 2026 - March 24, 2026). Investors who purchased ImmunityBio securities during this period and suffered losses have until May 26, 2026, to apply to be appointed as lead plaintiff.

• Benzinga·26d ago

  BIO-key Q1 Bottom-Line Improves on 34% Rise in Revenue; Expects Q2 Profitability on 65% Revenue Increase; Investor Call Today at 10am ET

  <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">HOLMDEL, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=js7cAfYQjbYPk8wJqUs4Mbl6SDaYfuX-kMU9hzQ3cV_9UEStki2EWwCuErD6CWOUwGjLYqYfQf0XX4Bv57mOO8LrMV2TYuGb4mFPL_IV8oA=" rel="nofollow" target="_blank" rel="nofollow">BIO-key<sup>®</sup> International, Inc.</a> (OTC Markets: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its first quarter (Q1'26) results and first half of 2026 (1H'26) outlook. BIO-key will host an investor call today at 10:00am ET (details below).</p> <p align="justify"><strong>Financial Highlights: </strong></p> <ul type="disc"> <li style="margin-bottom:8pt; text-align:justify;">Q1'26 revenues increased 34% to $2.15M vs. Q1'25 and 74% vs. Q4'25</li> <li style="margin-bottom:8pt; text-align:justify;">Q1'26 net loss improved to $(165K) vs. $(737K) in Q1'25 and $(1.722M) in Q4'25</li> <li style="margin-bottom:8pt; text-align:justify;">Q1'26 ending cash and cash equivalents position of $2.24M</li> <li style="margin-bottom:8pt; text-align:justify;">Q1'26 ending shares outstanding of 1.08M<br /><br /></li> </ul> <p align="justify"><strong>Outlook:</strong></p> <ul type="disc"> <li style="margin-bottom:8pt; text-align:justify;">Q2'25 revenues expected to rise 65% to approx. $2.8M vs. $1.7M in

• GlobeNewswire Inc.·27d ago

  NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE

  Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.